2.21

2.64% -0.06

After Hours: 2.21

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.21, with a volume of 1.71M. It is down -2.64% in the last 24 hours and down -14.34% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$2.27

Open:

$2.3

24h Volume:

1.71M

Relative Volume:

0.73

Market Cap:

$743.81M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-6.3143

EPS:

-0.35

Net Cash Flow:

$-68.07M

1W Performance:

-2.64%

1M Performance:

-14.34%

6M Performance:

-21.07%

1Y Performance:

+24.16%

1-Day Range:

$2.20

$2.33

1-Week Range:

$2.20

$2.375

52-Week Range:

$1.67

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

203

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	2.21	743.81M	0	-75.80M	-68.07M	-0.35
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Feb 20, 2025

Nuvation Bio Inc. (NYSE:NUVB) Short Interest Up 14.3% in January - MarketBeat

Feb 20, 2025

Feb 19, 2025

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - The Eastern Progress Online

Feb 19, 2025

Feb 18, 2025

What Do Wall Street Analysts Think About Nuvation Bio Inc (NYSE: NUVB) Stock? - Stocks Register

Feb 18, 2025

Peapod Lane Capital LLC Makes New $1.04 Million Investment in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Feb 18, 2025

Feb 17, 2025

Nuvation Bio executive departs after key milestones By Investing.com - Investing.com Nigeria

Feb 17, 2025

Feb 14, 2025

Nuvation Bio executive departs after key milestones - MSN

Feb 14, 2025

Feb 13, 2025

Nuvation BioPending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst (NUVB) - Seeking Alpha

Feb 13, 2025

Feb 12, 2025

The Significance of Moving Averages in Nuvation Bio Inc Inc. (NUVB) Price Performance - The InvestChronicle

Feb 07, 2025